HUYA Bioscience and Biolake collaborate to boost China's pharma innovation platform

San Diego, USA-headquartered HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, has entered into a strategic alliance with Wuhan National Bio-industry Base, also known as Biolake. The alliance is expected to combine both parties’ resources to accelerate the development of pharmaceutical discoveries from China.

HUYA, which is also present in China, says it is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to enabling and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing HUYA’s expertise to advance these compounds for international markets.

Biolake is a national-level industry base established at the Wuhan East Lake Hi-tech Development Zone in Wuhan, the capital of the Hubei province and home to many academic and research institutions. Since the start of its construction in November 2008, Biolake has developed quickly and attracted more than 300 domestic and foreign bioscience enterprises to its campus. The park has been building the New Drug Incubation Public Service Platform, aiming to provide all-in-one solutions and one-stop services to facilitate industrialization and commercialization processes of new drugs.